Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. - Wikidata - wikimedia - TriplyDB

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

http://www.wikidata.org/entity/Q34572233

about

Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma Treatment of gastric cancer Critical appraisal of trastuzumab in treatment of advanced stomach cancer The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for hum Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma Current and emerging therapies in unresectable and recurrent gastric cancer Taxanes in the Treatment of Advanced Gastric Cancer Perioperative and Palliative Chemotherapy for Esophageal Cancer Advanced gastric cancer: Current treatment landscape and future perspectives Novel targets in the treatment of advanced gastric cancer: a perspective review Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly Personalized medicine in gastric cancer: Where are we and where are we going?Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer Neoadjuvant chemotherapy followed by surgery in gastric cancer patients with extensive lymph node metastasis Recent aspects for disseminated carcinomatosis of the bone marrow associated with gastric cancer: What has been done for the past, and what will be needed in future?Gastric cancer: The times they are a-changin'Second-line treatment of metastatic gastric cancer: Current options and future directions State of the art management of metastatic gastroesophageal cancer Companion diagnostics for the targeted therapy of gastric cancer Clinical utility of ramucirumab in advanced gastric cancer Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis Helicobacter pylori and interleukin-8 in gastric cancer S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis Gastric cancer review The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.Hepatoid adenocarcinoma of the stomach – a different histology for not so different gastric adenocarcinoma: a case report Immunotherapy for Gastroesophageal Cancer Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis.Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma.Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic Review

P2860

Q24186222-5395E334-34EB-444A-B833-127FB76A4C90 Q24602875-AC90A8CF-F43C-4B94-AB56-112641D661AC Q24604411-D2BB96A8-A209-46F3-B31F-5F18CA67A985 Q24633301-0B19C36B-4D8D-422F-BCF3-B329105032EF Q24649684-36DCF009-9C72-46B2-AB5E-3F822E509D7D Q26741530-4E0E8563-8A74-4416-821F-694274372A6E Q26745453-72F34848-76BB-454D-AB5E-41C99CB363EA Q26747708-4443F289-56A7-4569-A7E3-AA872F488EF0 Q26753865-AE2AC8EF-D612-485F-B864-D50C16597E83 Q26764934-1053BD0B-A484-4483-BFFF-0434FCF118CA Q26765208-ED65104A-AA1B-4DCE-9102-64D8C23132CF Q26771399-9055BA05-7CDB-4128-85E9-BECEC82D98CA Q26774521-80D13314-F87B-4FE1-B599-5F258B4F39CC Q26774538-8AF71395-C5DB-409D-B5E2-68540B03CCB7 Q26775081-9C7C628C-18AB-4B0F-9C14-0D4E2BFB13DB Q26775945-C94380AB-FFD7-4A3A-AA91-6A84A9316F3F Q26776195-28DE2DC0-68FA-4852-8E30-5D96E7CA2C27 Q26778027-69748BD1-609E-48C0-BBC6-EE2CBC48A645 Q26779217-8B2E5ADB-17E2-4D28-8F8B-27B4C64D577F Q26780298-CC89A0BF-9FB7-42B9-9E4D-C4B17D2DEE97 Q26785665-D20BEE2C-FEF4-4629-9DB1-487A7510D28F Q26798400-207410EA-64C7-4EE6-AB53-70681368C39B Q26801289-F4614731-E707-404E-A8C7-ABEF22100225 Q26865057-B6B133F9-7C49-41DC-88D4-BF691D423E20 Q26999701-ECA12E3B-4A52-48A7-91B4-555C3F7DEC23 Q27002415-A7C4F6A1-840E-42F2-A170-F7E88333FD11 Q27025793-5551038E-201C-4333-A5EB-06268FA3B1BA Q27318805-1A1D1B14-53B5-462E-9C48-223DFF4971AD Q27497441-6A38ED02-D3C7-4724-A67B-1CDEFA7C7221 Q28069873-FBDBB7C3-A36D-4967-9075-9D72B9262880 Q28077666-7B6F405E-1239-493D-8D0E-AA1A84995CD9 Q28079750-D6E61249-E8FB-44AF-9BB4-63331B9AADED Q28084888-A764B1B9-998F-4B36-A9C5-BCD2AB31FEB9 Q28477038-58C8844C-0685-46BF-A527-1FCAFE588106 Q28544422-44B2EEAA-39D3-4BF3-AD9D-AF14C8B640D4 Q30239056-E9991299-1C75-48B3-B82E-C9110F322420 Q30491067-8AB4B08D-8F5F-421E-BB7F-E693E49E1CE1 Q30785622-20111B9B-6E5F-40C2-BDA5-8A507635B5E9 Q31012680-77AA163B-9093-48E0-B9DB-FFC9AB6781EC Q31125157-B007D545-7B56-4D34-9CF2-873328A8514F

P2860

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

http://www.wikidata.org/entity/Q34572233

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@ast

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@en

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@nl

type

label

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@ast

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@en

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@nl

prefLabel

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@ast

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@en

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@nl

P1433

Q34572233-DE7E7A4E-D46B-417A-A041-D7C43C3B407B

P1476

Q34572233-C09B88E1-AFB3-40BC-B1FE-BD4275442F44

P2093

Q34572233-0F12AF8A-0B62-4370-AEBD-2E9B8C02774C

Q34572233-1FA10401-568A-4085-B910-C4C0194EB1ED

Q34572233-235A342C-99C9-4E5E-A701-DC7BEA561FC8

Q34572233-27B824AC-5A1B-4147-BC10-AC6A7CC12F8F

Q34572233-618804A5-2813-4E07-9A28-64FBB8EA57E6

Q34572233-786FFA1D-3476-421E-A9F5-EA7562F80D27

Q34572233-7A4E71CA-9E75-430F-A632-21D73319391F

Q34572233-801B2974-AB16-4ECA-9493-30A25586AD5B

Q34572233-8219B29C-768D-45C8-B8DA-44E10B259D22

Q34572233-BE6CFF79-E4E5-485A-B4E1-A4E83CA4F43E

P304

Q34572233-E1FBCC6A-E84F-4B6E-989C-6624A297E3FC

P31

Q34572233-864768CE-2A98-4B09-9F4D-22C7B92A3943

P356

Q34572233-CFB8310A-4F0C-4696-8820-643177F62210

P407

Q34572233-3F037AFA-9B8A-41ED-B84D-2E6F0FA2B55B

P433

Q34572233-2B1DF597-985A-48D5-A4F4-984E90E89DE8

P478

Q34572233-A27F28E2-D521-4178-8914-815124FF31D1

P50

Q34572233-C105A659-2254-4D6C-9C90-3009B4893865

P577

Q34572233-69FA818E-2348-4DA8-A490-3A7BE0D01312

P698

Q34572233-8818F4DF-3CDC-4568-8253-55ECF27A7376

P356

JCO.2006.06.8429

P1433

Journal of Clinical Oncology

P1476

Phase III study of docetaxel a ...... eport of the V325 Study Group.

@en

P2093

Adriano Rodrigues

http://www.w3.org/2001/XMLSchema#string

Alejandro Majlis

http://www.w3.org/2001/XMLSchema#string

Corrado Boni

http://www.w3.org/2001/XMLSchema#string

Edouard Voznyi

http://www.w3.org/2001/XMLSchema#string

Jaffer A Ajani

http://www.w3.org/2001/XMLSchema#string

Manuel Constenla

http://www.w3.org/2001/XMLSchema#string

Marie-Laure Risse

http://www.w3.org/2001/XMLSchema#string

Miguel Fodor

http://www.w3.org/2001/XMLSchema#string

Sergei Tjulandin

http://www.w3.org/2001/XMLSchema#string

V325 Study Group

http://www.w3.org/2001/XMLSchema#string

P304

4991-4997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.06.8429

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Eric Van Cutsem

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17075117

http://www.w3.org/2001/XMLSchema#string